DUBLIN--(BUSINESS WIRE)--The "Global Sarcoma Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The sarcoma therapeutics market will register a CAGR of more than 8% by 2023.
The advent of regenerative medicine to drive growth in the market
One of the most advanced and extensively researched treatment methods is regenerative medicines, including gene therapy. In gene therapy, the mutated gene is taken from the patient and is modified genetically in laboratory and administered back into the patient.
Launch of novel drugs
The market is currently dominated by the sales of GLEEVEC for the treatment of sarcomas. The launch of novel drugs is expected to be one of the major growth drivers in the market.
High treatment costs
The cost of therapeutics is usually high as most of the drugs that are currently approved in the market are large molecules. These drugs are expensive due to the complex manufacturing process of biologicals and high R&D costs.
Key Players
- Bayer
- Eisai
- Eli Lilly
- Johnson & Johnson
- Novartis
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Soft tissue sarcoma - Market size and forecast 2018-2023
- Osteosarcoma - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bayer
- Eisai
- Eli Lilly
- Johnson & Johnson
- Novartis
For more information about this report visit https://www.researchandmarkets.com/research/nw662h/global_sarcoma?w=4
